Karachi: Liven Pharma Limited announced on January 20, 2026, a series of share transactions undertaken by its Executive Director, Kaashif Hussain Siddique. The transactions involved the sale of several tranches of shares, collectively altering the director’s stake in the company.
According to Liven Pharma Limited’s disclosure, the sales were executed under the Pakistan Stock Exchange’s regulations. The transactions took place on January 13, 2026, with Siddique disposing of a total of 45,243 shares. The sales were conducted through the Central Depository Company (CDC) in the ready market.
The share sales commenced with a batch of 4,500 shares, followed by subsequent sales of 3,827 shares, 25,000 shares, and smaller quantities, including a single share transaction. The cumulative effect of these transactions resulted in a change in Siddique’s cumulative percentage of shares, shifting from 43.06% to 43.02%.
According to information available from the Pakistan Stock Exchange (PSX), the sales by Siddique were executed at varying rates, although specific price details were not disclosed in the report. The cumulative percentage of shares held by the executive director saw a minor move, decreasing by 0.04 percentage points.
The disclosure of these transactions complies with PSX Regulation 5.5.4, which mandates the reporting of share dealings by directors, their spouses, and minor children. The designated market category for these transactions was the ready market, as specified in the report.
This series of transactions by a prominent executive within Liven Pharma Limited is expected to draw the attention of shareholders and market analysts, who will likely scrutinize the implications for the company’s governance and market position.